Literature DB >> 27340684

Proinflammatory cytokines and matrix metalloproteinases in CSF of patients with VZV vasculopathy.

Dallas Jones1, Enrique Alvarez1, Sean Selva1, Don Gilden1, Maria A Nagel1.   

Abstract

OBJECTIVE: To determine the levels of proinflammatory cytokines and matrix metalloproteinases (MMPs) in the CSF of patients with virologically verified varicella zoster virus (VZV) vasculopathy.
METHODS: CSF from 30 patients with virologically verified VZV vasculopathy was analyzed for levels of proinflammatory cytokines and MMPs using the Meso Scale Discovery multiplex ELISA platform. Positive CNS inflammatory disease controls were provided by CSF from 30 patients with multiple sclerosis. Negative controls were provided by CSF from 20 healthy controls.
RESULTS: Compared to multiple sclerosis CSF and CSF from healthy controls, levels of interleukin (IL)-8, IL-6, and MMP-2 were significantly elevated in VZV vasculopathy CSF.
CONCLUSIONS: CSF of patients with VZV vasculopathy revealed a unique profile of elevated proinflammatory cytokines, IL-8 and IL-6, along with elevated MMP-2. The relevance of these cytokines to the pathogenesis of VZV vasculopathy requires further study.

Entities:  

Year:  2016        PMID: 27340684      PMCID: PMC4907802          DOI: 10.1212/NXI.0000000000000246

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


Varicella zoster virus (VZV) is a neurotropic DNA alphaherpesvirus that infects >95% of humans worldwide. Primary infection causes varicella (chickenpox) after which VZV becomes latent in cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis. As VZV-specific cell-mediated immunity declines in elderly or immunosuppressed individuals, VZV reactivates to cause zoster (shingles). Zoster may be further complicated by infection of cerebral arteries, resulting in pathologic vascular remodeling and stroke (VZV vasculopathy). VZV vasculopathy is associated with a thickened intima composed of myofibroblasts, a paucity of smooth muscle cells in media, and disruption of the internal elastic lamina.[1] Key mediators in vascular remodeling associated with VZV vasculopathy are proinflammatory cytokines that promote cell migration, proliferation and tissue damage, as well as matrix metalloproteinases (MMPs) that degrade extracellular matrix to promote tissue remodeling and infiltration of immune cells.[2] Thus, we examined levels of proinflammatory cytokines and MMPs in the CSF of patients with virologically confirmed VZV vasculopathy.

METHODS

Standard protocol approvals, registrations, and patient consents.

Deidentified CSF from patients with multiple sclerosis (MS) and healthy controls was provided by the Rocky Mountain Multiple Sclerosis Center Biorepository, whose collection protocol for CSF was approved by the Colorado Multiple Institutional Review Board (12-0968). Deidentified, archived CSF from patients with VZV vasculopathy was obtained from the laboratory of Don Gilden, which receives multiple specimens to confirm or repudiate the diagnosis of VZV vasculopathy.

Cerebrospinal fluid.

Three groups of deidentified CSF were obtained according to Colorado institutional review board guidelines. The first group was CSF from 30 patients with virologically verified VZV vasculopathy,[3] defined as patients who presented with TIAs or stroke and whose CSF contained anti-VZV immunoglobulin G antibodies by ELISA (50% women, average age 56.7 years, range 20–75 years). The second group was CSF from 30 positive control CNS inflammatory disease patients with MS, including 17 with relapsing-remitting MS, 2 of whom were taking interferon (IFN) beta-1a or corticosteroids, and 13 patients with primary progressive MS (70% women, average age 44.3 years, range 24–62 years). The third group (negative control) was CSF from 20 healthy patients with no history of neurologic disease (90% women, average age 36.6 years, range 18–65 years). All CSF samples were centrifuged within 30 minutes at 800 rpm at 4°C for 5 minutes, and the supernatant was stored at −80°C until use.

Multiplex electrochemiluminescence immunoassay.

Levels of 10 cytokines in the liquid phase of the CSF, including IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IFN gamma (IFNγ), and tumor necrosis factor α (TNF-α), were measured using the Meso Scale Discovery Proinflammatory Panel 1 kit (Rockville, MD) according to the manufacturer's instructions. Levels of 5 MMPs in the liquid phase of CSF, i.e., MMP-1, -2, -3, -9, and -10, were measured using Meso Scale Discovery's MMP 2-Plex and MMP 3-Plex Ultra-Sensitive kits (Rockville, MD) according to the manufacturer's instructions. Cytokine and MMP concentrations were calculated by reference to a standard curve for each molecule derived using various concentrations of the standards assayed in the same manner as the CSF samples. The lower and upper limits of detection were calculated based on the concentration of signal equal to 2.5 SDs above the zero calibrator and below the upper plateau of the standards curve, respectively. All samples were analyzed in duplicate.

Statistical analysis.

Kruskal-Wallis analysis was used to compare differences among the 3 groups and between individual groups.

RESULTS

Cytokine levels in VZV vasculopathy CSF.

Significantly increased levels of IL-8 (p < 0.0001), IL-6 (p = 0.007), and IL-12p70 (p = 0.011) were found in VZV vasculopathy CSF compared to those in MS CSF, as well as significantly increased levels of IL-8 (p < 0.0001), IL-6 (p = 0.0001), IFNγ (p = 0.0004), TNF-α (p = 0.0012), IL-1β (p = 0.006), and IL-2 (p = 0.01) in VZV vasculopathy CSF compared to healthy control patient CSF. Levels of IL-8 (p < 0.004), IL-6 (p = 0.002), IFNγ (p < 0.0001), TNF-α (p < 0.0001), IL-1β (p < 0.0001), IL-2 (p < 0.0001), and IL-10 (p < 0.0001) were also significantly increased in MS CSF as compared to those in healthy control patient CSF (table, figure 1).
Table.

Meso Scale Discovery analyte levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

Figure 1.

Cytokine levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

Levels of IL-8 (p < 0.0001), IL-6 (p = 0.007) and (H) IL-12p70 (p = 0.011) were significantly higher in VZV vasculopathy CSF than those in MS CSF. Compared to CSF from healthy controls, (A) IL-8 (p < 0.0001), (B) IL-6 (p = 0.0001), (C) IFNγ (p = 0.0004), (D) TNF-α (p = 0.0012), (E) IL-1β (p = 0.006), and (F) IL-2 (p = 0.01) levels were significantly higher in VZV vasculopathy CSF, and levels of IL-8 (p < 0.004), IL-6 (p = 0.002), IFNγ (p < 0.0001), TNF-α (p < 0.0001), IL-1β (p < 0.0001), IL-2 (p < 0.0001), and (G) IL-10 (p < 0.0001) were significantly higher in MS CSF. (I) IL-4 and (J) IL-13 levels did not differ significantly among the 3 groups. Each dot represents cytokine values for individual patients; solid bars represent median CSF cytokine levels for each group. Dotted lines represent lower limits of detection for each cytokine. The asterisk represents statistically significant differences in median cytokine levels among the 3 groups. IFNγ = interferon gamma; IL = interleukin; MS = multiple sclerosis; TNF-α = tumor necrosis factor α; VZV = varicella zoster virus.

Meso Scale Discovery analyte levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

Cytokine levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

Levels of IL-8 (p < 0.0001), IL-6 (p = 0.007) and (H) IL-12p70 (p = 0.011) were significantly higher in VZV vasculopathy CSF than those in MS CSF. Compared to CSF from healthy controls, (A) IL-8 (p < 0.0001), (B) IL-6 (p = 0.0001), (C) IFNγ (p = 0.0004), (D) TNF-α (p = 0.0012), (E) IL-1β (p = 0.006), and (F) IL-2 (p = 0.01) levels were significantly higher in VZV vasculopathy CSF, and levels of IL-8 (p < 0.004), IL-6 (p = 0.002), IFNγ (p < 0.0001), TNF-α (p < 0.0001), IL-1β (p < 0.0001), IL-2 (p < 0.0001), and (G) IL-10 (p < 0.0001) were significantly higher in MS CSF. (I) IL-4 and (J) IL-13 levels did not differ significantly among the 3 groups. Each dot represents cytokine values for individual patients; solid bars represent median CSF cytokine levels for each group. Dotted lines represent lower limits of detection for each cytokine. The asterisk represents statistically significant differences in median cytokine levels among the 3 groups. IFNγ = interferon gamma; IL = interleukin; MS = multiple sclerosis; TNF-α = tumor necrosis factor α; VZV = varicella zoster virus.

MMP levels in VZV vasculopathy CSF.

CSF MMP-2 levels were significantly increased in patients with VZV vasculopathy compared to those in MS CSF (p = 0.0001), and significantly higher levels of MMP-1 (p = 0.0002), MMP-2 (p = 0.0001), MMP-3 (p = 0.0002), MMP-9 (p < 0.0001), and MMP-10 (p < 0.0001) were detected in VZV vasculopathy CSF compared to those in healthy control patient CSF; MMP-1 (p = 0.0009), MMP-2 (p = 0.0001), MMP-3 (p < 0.0001), MMP-9 (p < 0.0001), and MMP-10 (p < 0.0001) levels were significantly higher in CSF from patients with MS than those in controls (table, figure 2).
Figure 2.

MMP levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

MMP-2 levels were significantly higher in VZV vasculopathy CSF than those in MS CSF (p = 0.0001). Compared to CSF from healthy controls, levels of (A) MMP-1 (p = 0.0002), (B) MMP-2 (p = 0.0001), (C) MMP-3 (p = 0.0002), (D) MMP-9 (p < 0.0001), and (E) MMP-10 (p < 0.0001) were significantly higher in VZV vasculopathy, and levels of MMP-1 (p = 0.0009), MMP-2 (p = 0.0001), MMP-3 (p < 0.0001), MMP-9 (p < 0.0001), and MMP-10 (p < 0.0001) were significantly increased in CSF from patients with MS. Each dot represents MMP values from an individual patient, and solid bars represent median CSF MMP levels for each group. Dotted lines represent lower limits of detection for each MMP. The asterisk represents statistically significant differences in median MMP levels among the 3 groups. MMP = matrix metalloproteinase; MS = multiple sclerosis; VZV = varicella zoster virus.

MMP levels in CSF from patients with VZV vasculopathy, patients with MS, and from healthy controls

MMP-2 levels were significantly higher in VZV vasculopathy CSF than those in MS CSF (p = 0.0001). Compared to CSF from healthy controls, levels of (A) MMP-1 (p = 0.0002), (B) MMP-2 (p = 0.0001), (C) MMP-3 (p = 0.0002), (D) MMP-9 (p < 0.0001), and (E) MMP-10 (p < 0.0001) were significantly higher in VZV vasculopathy, and levels of MMP-1 (p = 0.0009), MMP-2 (p = 0.0001), MMP-3 (p < 0.0001), MMP-9 (p < 0.0001), and MMP-10 (p < 0.0001) were significantly increased in CSF from patients with MS. Each dot represents MMP values from an individual patient, and solid bars represent median CSF MMP levels for each group. Dotted lines represent lower limits of detection for each MMP. The asterisk represents statistically significant differences in median MMP levels among the 3 groups. MMP = matrix metalloproteinase; MS = multiple sclerosis; VZV = varicella zoster virus.

DISCUSSION

Because vascular remodeling is caused, in part, by inflammation and degradation of the extracellular matrix, we analyzed the levels of proinflammatory cytokines and MMPs in CSF from patients with VZV vasculopathy compared to inflammatory CSF from patients with MS and CSF from healthy controls. Elevated levels of IL-8, IL-6, IL-1β, TNF-α, IFNγ, and IL-2, as well as MMP-1, -2, -3, -9 and -10, in patients with VZV vasculopathy and patients with MS are consistent with the inflammatory nature of both disorders. The specific elevation of IL-8 in VZV vasculopathy CSF compared to MS CSF and CSF from healthy controls is important because it is a proinflammatory cytokine/chemokine that recruits neutrophils, consistent with an abundance of neutrophils in cerebral arteries in early VZV vasculopathy,[2] in zoster vesicular fluid,[4] and in the CSF of patients with VZV inflammatory brainstem disease.[5] The significant elevation of IL-6 in VZV vasculopathy CSF compared to CSF of both patients with MS and healthy controls likely reflects its proinflammatory role in inducing differentiation of macrophages,[6] which are prominent in VZV-infected cerebral arteries of patients with VZV vasculopathy.[2] IL-6 also induces smooth muscle cell migration and proliferation,[7] which contribute to myofibroblast accumulation in the thickened intima of VZV-infected cerebral arteries.[1] Increased levels of IL-12p70 in some VZV vasculopathy CSF compared to MS CSF likely mirrors T cell activation and secretion of inflammatory cytokines, consistent with the prevalence of T cells in VZV-infected arteries.[2] Unlike VZV vasculopathy CSF, that of patients with MS showed elevated IL-10 levels, consistent with an earlier report[8] and with the role of IL-10 in promoting antibody production in this B cell–driven disease. The significant elevation of MMP-2 in VZV vasculopathy CSF compared to MS CSF and CSF of healthy controls most likely reflects increased degradation of the extracellular matrix in VZV-infected arteries. Our findings of elevated MMPs in VZV vasculopathy and MS CSF support the role of multiple classes of MMPs in degradation of the extracellular matrix, tissue remodeling, and angiogenesis associated with inflammatory CNS diseases. Finally, the pathology of both intracerebral VZV vasculopathy and giant cell arteritis (GCA) is identical and characterized by granulomatous arteritis. Furthermore, VZV antigen is present in both cerebral arteries of patients with VZV vasculopathy and in the temporal arteries of patients with GCA.[9] Thus, GCA is likely to be an extracranial form of VZV vasculopathy in which the temporal artery is primarily affected. Consistent with this notion are the significantly increased levels of IL-8, IL-6, and MMP-2 in VZV vasculopathy CSF compared to MS CSF and control CSF, which parallel elevated levels of (1) IL-8 and neutrophils in the blood of patients with GCA during corticosteroid taper,[10] (2) IL-6 in the serum of patients with GCA,[11] and (3) MMP-2 in temporal artery biopsies and in the aorta of patients with GCA.[12]
  12 in total

Review 1.  Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature.

Authors:  Aaron Haug; Ravi Mahalingam; Randall J Cohrs; D Scott Schmid; John R Corboy; Don Gilden
Journal:  J Neurol Sci       Date:  2010-02-19       Impact factor: 3.181

2.  Varicella zoster virus vasculopathy: analysis of virus-infected arteries.

Authors:  M A Nagel; I Traktinskiy; Y Azarkh; B Kleinschmidt-DeMasters; T Hedley-Whyte; A Russman; E M VanEgmond; K Stenmark; M Frid; R Mahalingam; M Wellish; A Choe; R Cordery-Cotter; R J Cohrs; D Gilden
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

3.  Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells.

Authors:  T Nabata; S Morimoto; E Koh; T Shiraishi; T Ogihara
Journal:  Biochem Int       Date:  1990

4.  Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.

Authors:  Don Gilden; Teresa White; Nelly Khmeleva; Anna Heintzman; Alexander Choe; Philip J Boyer; Charles Grose; John E Carpenter; April Rempel; Nathan Bos; Balasubramaniyam Kandasamy; Kelly Lear-Kaul; Dawn B Holmes; Jeffrey L Bennett; Randall J Cohrs; Ravi Mahalingam; Naresh Mandava; Charles G Eberhart; Brian Bockelman; Robert J Poppiti; Madhura A Tamhankar; Franz Fogt; Malena Amato; Edward Wood; Vikram Durairaj; Steve Rasmussen; Vigdis Petursdottir; Lea Pollak; Sonia Mendlovic; Denis Chatelain; Kathy Keyvani; Wolfgang Brueck; Maria A Nagel
Journal:  Neurology       Date:  2015-02-18       Impact factor: 9.910

5.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in giant cell arteritis: an immunocytochemical study.

Authors:  T Tomita; K Imakawa
Journal:  Pathology       Date:  1998-02       Impact factor: 5.306

6.  Varicella-zoster virus vasculopathy: immune characteristics of virus-infected arteries.

Authors:  Maria A Nagel; Igor Traktinskiy; Kurt R Stenmark; Maria G Frid; Alexander Choe; Don Gilden
Journal:  Neurology       Date:  2012-12-12       Impact factor: 9.910

7.  The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy.

Authors:  M A Nagel; B Forghani; R Mahalingam; M C Wellish; R J Cohrs; A N Russman; I Katzan; R Lin; C J Gardner; D H Gilden
Journal:  Neurology       Date:  2007-02-07       Impact factor: 9.910

8.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.

Authors:  J Hernández-Rodríguez; M Segarra; C Vilardell; M Sánchez; A García-Martínez; M J Esteban; C Queralt; J M Grau; A Urbano-Márquez; A Palacín; D Colomer; M C Cid
Journal:  Rheumatology (Oxford)       Date:  2003-12-16       Impact factor: 7.580

9.  The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus.

Authors:  Lucie Sosvorova; Radmila Kanceva; Josef Vcelak; Lyudmila Kancheva; Milan Mohapl; Luboslav Starka; Eva Havrdova
Journal:  Neuro Endocrinol Lett       Date:  2015-12       Impact factor: 0.765

10.  Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression.

Authors:  Suchita Nadkarni; Jesmond Dalli; Jane Hollywood; Justin C Mason; Bhaskar Dasgupta; Mauro Perretti
Journal:  Circ Res       Date:  2013-10-24       Impact factor: 17.367

View more
  9 in total

Review 1.  Varicella zoster virus vasculopathy: The expanding clinical spectrum and pathogenesis.

Authors:  Maria A Nagel; Dallas Jones; Ann Wyborny
Journal:  J Neuroimmunol       Date:  2017-03-18       Impact factor: 3.478

2.  Interleukin-6 and type 1 interferons inhibit varicella zoster virus replication in human neurons.

Authors:  Christina N Como; Catherine M Pearce; Randall J Cohrs; Nicholas L Baird
Journal:  Virology       Date:  2018-07-04       Impact factor: 3.616

3.  Elevated serum substance P during simian varicella virus infection in rhesus macaques: implications for chronic inflammation and adverse cerebrovascular events.

Authors:  Andrew N Bubak; Vicki Traina-Dorge; Christina N Como; Brittany Feia; Catherine M Pearce; Laura Doyle-Meyers; Arpita Das; Jayme Looper; Ravi Mahalingam; Maria A Nagel
Journal:  J Neurovirol       Date:  2020-09-22       Impact factor: 2.643

4.  Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Andrew N Bubak
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

5.  Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis.

Authors:  Catharina Conrad; Kristina Dorzweiler; Miles A Miller; Douglas A Lauffenburger; Herwig Strik; Jörg W Bartsch
Journal:  Fluids Barriers CNS       Date:  2017-08-14

6.  Varicella zoster virus differentially alters morphology and suppresses proinflammatory cytokines in primary human spinal cord and hippocampal astrocytes.

Authors:  Andrew N Bubak; Christina N Como; Anna M Blackmon; Dallas Jones; Maria A Nagel
Journal:  J Neuroinflammation       Date:  2018-11-15       Impact factor: 8.322

7.  Cellular Stress Response to Varicella-Zoster Virus Infection of Human Skin Includes Highly Elevated Interleukin-6 Expression.

Authors:  Keith W Jarosinski; John E Carpenter; Erin M Buckingham; Wallen Jackson; Kevin Knudtson; Jennifer F Moffat; Hirohito Kita; Charles Grose
Journal:  Open Forum Infect Dis       Date:  2018-05-22       Impact factor: 3.835

8.  The 17th Rocky Mountain Virology Association Meeting.

Authors:  Joel Rovnak; Rushika Perera; Matthew W Hopken; Jenna Read; Derrick M Waller; Randall J Cohrs
Journal:  Viruses       Date:  2017-11-08       Impact factor: 5.048

9.  Varicella zoster virus-infected cerebrovascular cells produce a proinflammatory environment.

Authors:  Dallas Jones; C Preston Neff; Brent E Palmer; Kurt Stenmark; Maria A Nagel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.